p21(WAF1) mutations and human malignancies

Leukemia and Lymphoma

Volumn 26, Issue 1-2, 1997, Pages 35-41

  Shiohara, Masaaki ^b   Koike, Kenichi ^b   Komiyama, Atsushi ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclin dependent kinase inhibitor; Human malignancies; Mutations; p21(WAF1)

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DNA DIRECTED DNA POLYMERASE DELTA; PROTEIN P21; PROTEIN P53; ONCOPROTEIN;

CANCER INCIDENCE; CARCINOGENESIS; CELL CYCLE; CELL TRANSFORMATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; MOUSE; MOUSE MUTANT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; ANIMAL; DRUG ANTAGONISM; GENETICS; MUTATION; NEOPLASM; PHYSIOLOGY;

ANIMALS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS;

EID: 0030610221     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709109155     Document Type: Review

References (75)

1. Nigro, J. M., Baker, S. J., Presinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C. and Vogelstein, B. (1989). Mutations in the p53 gene occur in diverse human tumor types, Nature, 342, 705-708.
2. Imamura, J., Miyoshi, I. and Koeffler, H. P. (1994) p53 in hematologic malignancies, Blood, 84, 2412-2421.
3. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S. III, Johnson, B. E. and Skolnick, M. H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264, 436-440.
4. INK4 in human cancer, Proc. Natl. Acad. Sci. USA., 91, 11045-11049.
5. Takeuchi, S., Bartram, C. R., Seriu, T. Miller, C. W., Tobler, A., Janssen, J. W. G., Reiter, A., Ludwig, W-D., Zimmermann, M., Scwaller, J., Lee, E., Miyoshi, I. and Koeffler, H. P. (1995). Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/ MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood, Blood, 86, 755-760.
6. Hatta, Y., Hirama, T., Miller, C. W., Yamada, Y., Tomonaga, M. and Koeffler, H. P. (1995) Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia, Blood, 85, 2699-2704.
7. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993). p21 is a universal inhibitor of cyclin kmases, Nature, 366, 701-704.
8. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases, Cell, 75, 805-816.
9. El-Deiry, W. S., Tokino, T., Velculescu, V., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817-825.
10. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M. and Smith, J. R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen, Exp. Cell Res., 211, 90-98
11. Sherr, C. J. (1994). G1 phase progression: Cycling on cue, Cell. 79, 551-555.
12. Nurse, P. (1994). Ordering S phase and M phase in the cell cycle, Cell, 79, 547-550.
13. Morgan, D. O. (1995). Principles of CDK regulation, Nature, 374, 131-134.
14. Kato, J., Matsuoka, M., Strom, D. K. and Sherr, C. J. (1994). Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activaling kinase, Mol. Cell Biol., 14, 2713-2721.
15. Fisher, R. P. and Morgan, D. O. (1994). A novel cyclin associates with Mo15/CDK7 to form the CDK-activating kinase, Cell, 78, 713-724.
16. Makela, T. P., Tassan, J. P., Nigg, E. A., Frutiger, S., Hughes, G. J. and Weinberg, R. A. (1994). A cyclin associated with the CDK-activating kinase MO15, Nature, 371, 254-257.
17. Sherr, C. J. (1993). Mammalian G1 cyclins, Cell, 73, 1059-1065.
18. Xiong, Y., Zhang, H. and Beach, D. (1992). D-type cyclins associates with multiple protein kinases and the DNA replication and repair factor PCNA, Cell, 71, 505-514.
19. Meyerson, M. and Harlow, E. (1994). Identification of a G1 kinase activity for cdk6, a novel cyclin D partner, Mol. Cell Biol., 14, 2077-2086.
20. Matsushime, H., Roussel, M. F., Ashmun, R. A. and Sherr, C. J. (1991). Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle, Cell, 65, 701-713.
21. Dulic, V., Lees, E. and Reed, S. I. (1992). Association of human cyclin E with a periodic G1-S phase protein kinase, Science, 257, 1958-1961.
22. Girard, F., Strausfeld, U., Fernandez, A. and Lamb, N. J. (1991). Cyclin A is required for the onset of DNA replication in mammalian fibroblasts, Cell, 67, 1169-1179.
23. Nevins, J. R. (1992). E2F: A link between the Rb tumor suppressor protein and viral oncoproteins, Science, 258, 424-429.
24. Serrano, M., Hannon, G. J. and Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4, Nature, 366, 704-707.
25. INK4B is a potential effector of TGF-β-induced cell cycle arrest, Nature, 371, 257-261.
26. INK4/MTS2 - related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8, 2939-2952.
27. Mirai, H., Roussel, M. F., Kato, J., Ashmun, R. A. and Sherr, C. J. (1995). Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kinases CDK4 and CDK6, Mol Cell Biol., 15, 2672-2681.
28. Gu, Y., Turck, C. W. and Morgan, D. O. (1993). Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit, Nature, 366, 707-710.
29. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
30. Toyoshima, H. and Hunter, T. (1994). p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21, Cell, 78, 67-74.
31. Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution, Genes Dev., 9, 639-649.
32. CIP1 cdk inhibitory family, is a candidate tumor suppressor gene, Genes Dev., 9, 650-662.
33. Kip1) of cyclin-dependent kinase 4 activation, Cell, 79, 487-496
34. Polyak, K., Kato, J-Y., Solomon, M., Sherr, C. J., Massague, J., Roberts, J. M. and Koff, A. (1994). p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest, Genes Dev., 8, 9-22.
35. Zhang, H., Xiong, Y. and Beach, D. (1993). Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes, Mol. Biol. Cell, 4, 897-906.
36. Xiong, Y., Zhang, H. and Beach, D. (1993) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation, Genes Dev., 7, 1572-1583.
37. Chen, J., Jackson, P. K., Kirschner, M. W. and Dutta, A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA, Nature, 374, 386-388.
38. Cip1, Nature, 375, 159-161.
39. Sdi1/CIP1/WAF1, EMBO, J., 14, 555-563.
40. Cip1 cyclin-dependent kinase inhibitor, Oncogene, 10, 2281-2287
41. Li, R., Waga, G., Hannon, G. J., Beach, D. and Stillman, B. (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair, Nature, 371, 534-537.
42. Shim, J., Lee, H., Park, J., Kim, H. and Choi, E-J. (1996). A non-enzymatic p21 protein inhibitor of stress-activated protein kinases, Nature, 381, 804-807.
43. Li, Y., Jenkins, C. W., Nichols, M. A. and Xiong, Y. (1994). Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21, Oncogene, 9, 2261-2268
44. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E. Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. and Vogelstein, B. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
45. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E. and Givol, D. (1994). Induction of WAF1/CIP1 by a p53-independent pathway, Cancer Res., 54, 3391-3395.
46. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A. and El-Houseini, M. E. (1994). Induction of p21 (WAF-1/CIP1) during differentiation, Oncogene, 9, 3389-3396.
47. Jiang, H., Lin, J., Su, Z-Z., Collart, F. R., Huberman, E. and Fisher, P. B. (1994). Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53, Oncogene, 9, 3397-3406.
48. WAF1/CIP1/SDI1 differentiating human leukemic cells, J. Clin. Invest., 95, 973-979.
49. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B. and Jacks, T. (1995). p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage, Genes Dev., 9, 935-944.
50. Shiohara, M., Akashi, M., Gombart, A. F., Yang, R. and Koeffler, H. P. (1996). Tumor necrosis factor α: Posttranscriptional stabilization of WAF1 mRNA in p53-deficient human leukemic cells, J. Cell Physiol., 166, 568-576.
51. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y. and Wang, X-F. (1995). Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism, Proc. Natl. Acad. Sci. USA., 92, 5545-5549.
52. Li, C-Y., Suardet, L. and Little, J. B. (1995). Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect, J. Biol Chem., 270, 4971-4974.
53. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travail, S., Deisseroth, A. B. and Mercer, W. E. (1995). p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55, 668-674.
54. Akashi, M., Hachiya, M., Osawa, Y., Spirin, K., Suzuki, G. and Koeffler, H. P. (1995). Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells, J. Biol. Ctem., 270, 19181-19187.
55. Cip1 in muscle and other terminally differentiating cells, Science, 267, 1024-1027.
56. Guo, K., Wang, J., Andres, V., Smith, R. C. and Walsh, K. (1995). MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation, Mol. Cell Biol., 15, 3823-3829.
57. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D. and Lassar, A. B. (1995). Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD, Science, 267, 1018-1021.
58. Skapek, S. X., Rhee, J., Spicer, D. B. and Lassar, A. B. (1995). Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase, Science, 267, 1022-1024.
59. Missero, C., Calautti, E., Eckner, R., Chin, J., Tsai, L. H., Livingston, D. M. and Dotto, G. P. (1995). Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation, Proc Natl. Acad. Sci. USA., 92, 5451-5455.
60. Gartenhaus, R. B., Wang, P. and Hoffmann, P. (1996). Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway, Proc. Natl. Acad Sci. USA., 93, 265-268.
61. WAF1/CIP1 in breast epithelial cells. Cancer Res., 55, 4520-4524.
62. waf1/cip1, Genes Dev., 8, 2817-2830.
63. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control, Cell, 82, 675-684.
64. Gorospe, M. and Holbrook, N. J. (1996). Role of p21 in prostaglandin A2-mediated cellular arrest and death, Cancer Res., 56, 475-479.
65. Shiohara, M., Gombart, A. F., Herman, J. D. and Koeffler, H. P. manuscript in preparation
66. Yang, Z-Y., Perkins, N. D., Ohno, T., Nabel, E. G. and Nabel, G. J. (1995). The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Medicine, 1, 1052-1056.
67. WAF1, Cancer Res., 55, 4536-4539.
68. Shiohara, M., El-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B. and Koeffler, H. P. (1994). Absence of WAF1 mutations in a variety of human malignancies, Blood, 84, 3781-3784.
69. CKI gene in malignant gliomas, Int. J Cancer, 62, 115-117.
70. Bhatia, K., Fan, S., Spangler, G., Weintraub, M., O'Connor, P. M., Judde, J. G. and Magrath, I. (1995). A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma, Cancer Res., 55, 1431-1435.
71. Hirano, Y., Yamato, K. and Tsuchida, N. (1995). A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down, Oncogene, 10, 1879-1885.
72. Wang, Q. M., Jones, J. B. and Studzinski, G. P. (1996). Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1, 25-dihydroxyvitamm D3 in HL60 cells. Cancer Res., 56, 264-267.
73. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function, Genes Dev., 8, 2939-2952
74. Hunter, T. and Pines, J. (1994). Cyclins and cancer. II. cyclin D and CDK inhibitors come of age. Cell 79, 573-582.
75. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G. Issa, J-P. J., Davidson, N. E., Sidransky, D. and Baylin, S. B. (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55, 4525-4530.